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Transcriptional regulators, such as SoxS, RamA, MarA, and Rob, which upregulate the AcrAB efflux pump, have been shown to
be associated with multidrug resistance in clinically relevant Gram-negative bacteria. In addition to the multidrug resistance
phenotype, these regulators have also been shown to play a role in the cellular metabolism and possibly the virulence potential of
microbial cells. As such, the increased expression of these proteins is likely to cause pleiotropic phenotypes. Klebsiella pneu-
moniae is a major nosocomial pathogen which can express the SoxS, MarA, Rob, and RamA proteins, and the accompanying pa-
per shows that the increased transcription of ramA is associated with tigecycline resistance (M. Veleba and T. Schneiders, Anti-
microb. Agents Chemother. 56:4466–4467, 2012). Bioinformatic analyses of the availableKlebsiella genome sequences show that
an additional AraC-type regulator is encoded chromosomally. In this work, we characterize this novel AraC-type regulator,
hereby called RarA (Regulator of antibiotic resistance A), which is encoded in K. pneumoniae, Enterobacter sp. 638, Serratia pro-
teamaculans 568, and Enterobacter cloacae. We show that the overexpression of rarA results in a multidrug resistance phenotype
which requires a functional AcrAB efflux pump but is independent of the other AraC regulators. Quantitative real-time PCR
experiments show that rarA (MGH 78578 KPN_02968) and its neighboring efflux pump operon oqxAB (KPN_02969_02970) are
consistently upregulated in clinical isolates collected from various geographical locations (Chile, Turkey, and Germany). Our
results suggest that rarA overexpression upregulates the oqxAB efflux pump. Additionally, it appears that oqxR, encoding a
GntR-type regulator adjacent to the oqxAB operon, is able to downregulate the expression of the oqxAB efflux pump, where
OqxR complementation resulted in reductions to olaquindoxMICs.
Multidrug resistance in Gram-negative bacteria is a significantissue in the treatment of infectious diseases. Research asso-
ciated with reduced antimicrobial susceptibility is largely focused
on specific mechanisms that confer high levels of antibiotic resis-
tance and are generally acquired extrinsically (18). In contrast,
genes that encode transcriptional regulators such as MarA, SoxS,
Rob, and RamA confer a low-level multidrug-resistant (MDR)
phenotype by increasing levels of efflux pump expression (1).
The study of these intrinsic genetic mechanisms is key to the
understanding of the development and persistence of antimicro-
bial resistance, as these intrinsic systems are generally encoded by
transcription factors that control a plethora of genes. In Esche-
richia coli and Salmonella spp., two major systems, namely, the
marAB and soxRS systems, have been extensively studied (3, 25).
In numerous studies involving multidrug-resistant clinical
strains, it has been shown thatmutations that alter the levels of the
MarA or SoxS proteins also lead to increased levels of the efflux
system AcrAB (20, 30). Generally, mutations that result in dere-
pression or activation generate the constitutive expression of the
MarA/SoxS proteins; however, transient induction of these intrin-
sic proteins can also occur through interaction with ligands such
as salicylate (5) or menadione (13).
Chromosomally intrinsic systems in E. coli andKlebsiella pneu-
moniae such as MarRAB and SoxRS have been shown to control
efflux pumps, particularly the AcrAB pump, which confers low-
level resistance to a variety of antibiotics and disinfectants (22).
Additionally, several global transcriptional profiling studies have
shown that other less-well-characterized efflux pumps and other
genes involved in cellular metabolism are also regulated by these
intrinsic systems (3, 24). Accordingly, studies show that the viru-
lence profiles and infectivity potential of bacteria can be altered on
the basis of the expression levels of these intrinsic regulators (4).
Addressing the role of accessory genes or operons associated with
or involved in antimicrobial resistance is an integral part of un-
derstanding the microbial response to antibiotic challenge, as an-
tibiotics have been shown to function as signaling molecules that
trigger specific transcriptional signals (7). Hence, it is evident
from these studies that the intrinsic resistome of bacteria consists
of genes thatmay be involved in awide variety of cellular functions
but which also provide protection against antibiotic challenge.
Klebsiella pneumoniae is a commonly encountered major nos-
ocomial pathogen that is increasingly multidrug resistant (12). As
in E. coli and Salmonella spp., transcription factors that mediate
multidrug resistance have been identified in K. pneumoniae (16,
27, 28). To date, most studies that have identified the role of tran-
scriptional regulators in the multidrug resistance phenotype have
shown that, in clinical K. pneumoniae isolates, increased expres-
sion of amarA-like gene, ramA, has been associated with upregu-
lation of the acrAB efflux pump andmultidrug resistance (27, 28).
In order to determine whether other intrinsic systems exist that
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can confer multidrug resistance in K. pneumoniae, we performed
bioinformatic analyses to mine the three sequenced K. pneu-
moniae genomes for AraC-type regulators. As a result of these
analyses, we have identified and characterized a novel AraC-type
regulator, KPN_02968 (designation based on MGH 78578 ge-
nome sequence), that confers a multidrug-resistant phenotype,
which we now call RarA (Regulator of antibiotic resistance A).
Bioinformatic analyses show that the rarA gene is encoded in K.
pneumoniae, Enterobacter sp. 638, Serratia proteamaculans 568,
and E. cloacae (Fig. 1A).
MATERIALS AND METHODS
Bacterial strains.A complete list of all bacterial strains and plasmids used
and constructed is shown in Table 1. The propagation of all strains was
either performed in LB broth at 37°Cwith shaking or LB agar at 37°C. The
targeted genetic mutants were generated from K. pneumoniae Ecl8 by the
use of a modified protocol as described by Merlin et al. (21). Briefly,
flanking regions of rarA were amplified using PCR primers (Co-Ci and
No-Ni 02968) (Table 2), and the products were then reamplified using the
outer flank primers, Co and No, which generated a PCR fragment that
contained both flanking regions but not rarA. This fragment was restric-
tion digested by the use of PstI and SalI (NEB, England) and cloned into
the pTOF25 replacement vector (21). The kanamycin resistance cassette
was excised from the recombinant pTOF3 plasmid by the use of NotI
excision and cloned between the flanking regions in the recombinant
pTOF25. This recombinant plasmid was electroporated into K. pneu-
moniae Ecl8, and a kanamycin-resistant variant was selected after growth
on selection plates at 30°C. The insertion was verified by PCR amplifica-
tion using the primers 02968delchkF and 02968delchkR. Similarly, for the
acrAB gene knockout, we used Co-acrB/Ci-acrB and No-acrA/Ni-acrA to
create the flanks. In this case, the overlap PCR product was restricted
using XhoI and PstI (NEB, England) prior to cloning and gene replace-
ment as described above.
Bioinformatic analyses. Amino acid identity was analyzed using
NCBI’s Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih
.gov) and the MarA amino acid sequence (KPN_01624) from the NCBI
entry Klebsiella pneumoniae subsp. pneumoniae MGH 78578 (accession
number NC_009648.1). To assess the genetic relatedness of the AraC reg-
ulators such as Rob, RamA, RarA, and SoxS, a phylogenetic tree was gen-
erated using the Phylogeny Analysis tool at LIRMM Methodes et Algo-
rithmes pour la Bio-informatique (http://www.phylogeny.fr/version2
_cgi/simple_phylogeny.cgi) (14) by inputting sequences of Rob
(KPN_04851), RamA (KPN_00556), RarA (KPN_02968), SoxS
(KPN_04462), and putative helix-turn-helix (HTH) AraC-type regulator
KPN_01709.
Antimicrobial susceptibility testing. Susceptibility testing was un-
dertaken as described by the British Society for Antimicrobial Chemo-
therapy (BSAC) guidelines using the agar dilutionmethod (2). Overnight
cultures were briefly diluted 104 in PBSmedium, and 5l of each dilution
was spotted on the LB agar plates supplemented with antibiotics. Plates
were incubated overnight at 37°C prior to scoring for growth. All MIC
tests were performed in triplicate.
Cloning and transformations.All primers used are shown in Table 2.
A recombinant plasmid containing the gene of interest, rarA
(KPN_02968), was constructed. Due to conflicting antibiotic resistance
determinants in the chromosomal gene knockouts, two plasmid recom-
binants (pACrarA-1 and pACrarA-2) harboring the rarA gene were con-
structed. The fragment for cloning into pACYC177 was amplified using
02968FB and 02968RS and restricted using the BamHI and ScaI enzymes
(New England BioLabs, United Kingdom). Similarly, the fragment for
cloning into pACYC184 was amplified using 02968HR and 02968BF and
FIG 1 (A) Comparison of genomic organizations of rarA (KPN_02968) locus in Klebsiella pneumoniae strain MGH 78578 to those of other Enterobacteriaceae
harboring the locus. (B) Predicted phylogenetic tree of MarA-type protein homologues in Klebsiella pneumoniae determined using PhyML 3.0 (14). The amino
acid sequences for MarA (KPN_01624), Rob (KPN_04851), RarA (KPN_02968), RamA (KPN_00556), SoxS (KPN_04462), and KPN_01709 were used in
Muscle alignment software to generate the phylogenetic tree. All amino acid sequences were obtained from the genome sequence of MGH 78578 (NC_009648).
Of note, different branch lengths denote relative amino acid identities.
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restricted using the BamHI and HindIII enzymes to generate pACrarA-2.
Depending on the strain, one of these constructs was then electroporated
or heat shock transformed into bacterial strains harboring the different
genetic deletions (shown in Table 1). In order to determine the effect of
oqxRmutations, the open reading frame (ORF) of oqxR (amplified using
OqxRBamHI and OqxRScaIR) was cloned into pACYC177 by the use of
the BamHI/ScaI restriction sites.
RNA extraction. RNA was extracted from relevant strains of K. pneu-
moniae or E. coli (Table 1) by the use of the TRIzol extraction method as
described previously (27). Briefly, cells were grown to themid-log phase at
37°C with shaking and then harvested by centrifugation at 3,000  g at
room temperature. The cell pellet was then resuspended in TRIzol reagent
(Invitrogen, Paisley, United Kingdom) and chloroform and centrifuged
to separate the phases. The upper phase was then precipitated using so-
dium acetate, glycogen, and 100% ethanol. The resulting pellet was
washed and resuspended in an appropriate amount of diethyl pyrocar-
bonate (DEPC)-treated water.
Real-timeRT-PCR.Quantitative real-time reverse transcription-PCR
(RT-PCR) was performed to assess levels of gene expression for rarA,
ramA, marA, soxS, and oqxA. 16S RNA was used as a control gene to
normalize cDNA levels. cDNA was generated using am AffinityScript
quantitative PCR (QPCR) cDNA synthesis kit (Agilent, United King-
dom). A Brilliant III Ultra-Fast SYBR green kit (Agilent, United King-
dom) was used for amplification, and experiments were conducted using
a Stratagene Mx3005P QPCR system (Agilent Technologies). The strains
used as controls when determining rarA, oqxA, ramA, and acrAB expres-
sion were wild-type and antibiotic-susceptible K. pneumoniae strain Ecl8
and its isogenic resistant variant K. pneumoniae Ecl8Mdr1 (Table 1). Ex-
pression levels were normalized against levels of 16S expression, and these
data were calibrated against expression levels of the sensitive Ecl8 strain as
the baseline to determine fold changes in expression. All data were ana-
lyzed using Agilent MxPro software.
Sequence studies. For sequence analysis, PCR amplification was un-
dertaken for intergenic regions (between rarA and oqxA—primers
02698intF and 02698intR) to determine whether any promoter-associ-
ated or ORF mutations result in increased expression of rarA. Addition-
ally, oqxR (KPN_02971), a putative regulator of the oqxAB efflux pump,
was sequenced (primers OqxRF and OqxRR) to identify any mutations
TABLE 1 List of strains used in experiments
Strain Relevant genotype and phenotypea Reference or source
E. coli strains
AG100 E. coli wt strain 11
AG100/pACrarA-1 AG100 pACrarA-1 (wt rarA cloned into pACYC177 (BamHI, ScaI), Kanr This work
AG100/pACYC177 AG100 pACYC177 (Kanr, Ampr) This work
AG100/pACrarA-2 AG100 pACrarA-2 (wt rarA cloned into pACYC184 [BamHI, HindIII]), Cmr This work
AG100/pACYC184 AG100 pACYC184 (Cmr, Tetr) This work
AG100A acrAB efflux pump-deleted strain 28
AG100A/pACrarA-2 AG100A pACrarA-2 (wt rarA cloned into pACYC184 [BamHI, HindIII]), Cmr This work
AG100A/pACYC184 AG100A pACYC184 (Cmr, Tetr) This work
MG1655 E. coli K-12 laboratory isolate In-house strain collection
MG1655/pACrarA-1 MG1655 pACrarA-1 (wt rarA cloned into pACYC177 [BamHI, ScaI]), Kanr This work
MG1655/pACYC177 MG1655 pACYC177 (Kanr, Ampr) This work
MG1655 marA marA-deleted strain S. B. Levy, L. McMurry
MG1655 marA/pACrarA-1 MG1655 marA pACrarA-1 (wt rarA cloned into pACYC177 [BamHI, ScaI]), Kanr This work
MG1655 marA/pACYC177 MG1655 marA pACYC177 (Kanr, Ampr) This work
AG100 soxS rob marA soxS-, rob-,marA-deleted strain S. B. Levy, L. McMurry
AG100 soxS rob marA/pACrarA-2 AG100 soxS rob marA pACrarA-2 (wt rarA cloned into pACYC184 [BamHI,
HindIII]), Cmr
This work
AG100 soxS rob marA/pACYC184 AG100 soxS rob marA pACYC184 (Cmr, Tetr) This work
K. pneumoniae strains
MGH 78578 ATCC 700721 19
Ecl8 K. pneumoniae wt strain 8
Ecl8/pACrarA-1 Ecl8 pACrarA-1 (wt rarA cloned into pACYC177 [BamHI, ScaI]), Kanr This work
Ecl8/pACYC177 Ecl8 pACYC177 (Kanr, Ampr) This work
Ecl8Mdr1 Spontaneous MDR mutant of Ecl8 10
Ecl8 ramA ramA-deleted strain derived from Ecl8 27
Ecl8 ramA/pACrarA-1 Ecl8 ramA pACrarA-1 (wt rarA cloned into pACYC177 [BamHI, ScaI]), Kanr This work
Ecl8 ramA/pACYC177 Ecl8 ramA pACYC177 (Kanr, Ampr) This work
Kp342 K. pneumoniae isolated from maize 9
Ecl8 acrAB acrAB-deleted strain derived from Ecl8, Kanr This work
Ecl8 acrAB/pACrarA-2 Ecl8 acrAB pACrarA-2 (wt rarA cloned into pACYC184 [BamHI, HindIII]), Cmr This work
Ecl8 acrAB/pACYC184 Ecl8 acrAB pACYC184 (Cmr, Tetr) This work
Ecl8 rarA rarA (KPN_02968)-deleted strain derived from Ecl8, Kanr This work
Ecl8 rarA/pACrarA-2 Ecl8 rarA pACrarA-2 (wt rarA cloned into pACYC184 [BamHI, HindIII]), Cmr This work
Ecl8 rarA/pACYC184 Ecl8 rarA pACYC184 (Cmr, Tetr) This work
TS152, TS165 K. pneumoniae clinical isolates (Turkey) 27
TS180, TS202 K. pneumoniae clinical isolates (Chile) 27
GC9, GC12, GC19, GC21 K. pneumoniae clinical isolate (Germany) This work
GC9, GC12, GC19, GC21/pACoqxR GC isolates pACoqxR (wt oqxR cloned into pACYC177 [BamHI, ScaI]), Kanr This work
GC9, GC12, GC19, GC21/pACYC177 GC isolates pACYC177 (Kanr, Ampr) This work
a wt, wild type; Kan, kanamycin; Amp, ampicillin; Cm, chloramphenicol; Tet, tetracycline.
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that could result in the upregulation of the oqxAB efflux pump
(KPN_02969, KPN_02970). Primers 02968FB and 02968RS were used to
verify the rarA gene in the recombinant plasmids pACrarA-1 and
pACrarA-2. Prior to sequencing, the PCR products were purified using a
Genejet purification kit (Fermentas, Germany), and the sequencing reac-
tions were performed using a BigDye Terminator 3.1 cycle sequencing kit
(Applied Biosystems) prior to the automated runs being performed at the
Genomics Core at Queen’s University Belfast’s Centre for Public Health,
City Hospital. The consensus sequence (based on both the forward and
reverse strands) were aligned and compared to the wild-type sequences
from NCBI using MultAlin software (http://multalin.toulouse.inra.fr
/multalin/multalin.html).
Mapping the TSS of rarA. The transcription start site (TSS) was
mapped according to themanufacturer’s instructions as outlined in the 5=
Rapid Amplification of cDNA Ends (RACE) kit (Invitrogen, Paisley,
UnitedKingdom). Briefly,DNase I-digestedRNAwas converted to cDNA
by the use of primer GSP1, prior to SNAP purification and TdT tailing
(Invitrogen, Paisley, United Kingdom). The dc-tailed cDNA was ampli-
fied using the Abridged anchor primer and GSP2 (Table 2). This was
followed by an additional round of amplifications using the Abridged
universal anchor primer and GSP3 (Table 2), yielding a product sized at
172 bp. The purified PCR product was TA cloned into pGEMTeasy vector
(Promega, Southampton, United Kingdom), and the insertion sequence
was verified using bidirectional sequencing. The junction between the C
tail and the start site of rarA open reading frame was taken to be the
transcriptional start site. Predictions of the putative 10 and 35 hex-
amers were determined using SoftBerry analysis of the intergenic region.
RESULTS
Bioinformatic analyses. In order to mine the K. pneumoniae ge-
nomes for other uncharacterized AraC-type transcriptional regu-
lators, we used the amino acid sequence for the prototype regula-
tor MarA (KPN_01624) from K. pneumoniae MGH 78578. We
focused on the top five hits from the BLAST analyses, in descend-
ing order of identity, which were Rob (53%), RamA (46%),
KPN_02968 (called rarA [46%]), SoxS (42%), and another puta-
tive AraC-type regulatory protein, KPN_01709 (34%). We de-
cided to focus on rarA in further work for two reasons: first, be-
cause of its higher level of identity toMarA, and second, because of
its predicted size of 121 amino acids being closer to that of the
subset of AraC regulators such as RamA, SoxS, and MarA rather
than the considerably larger KPN_01709 (326 amino acids). As
expected, the phylogenetic tree generated using MUSCLE for
multiple alignments of the five AraC regulators (Fig. 1B) shows
that KPN_02968 is closely related to the MarA, SoxS, and RamA
proteins; however, KPN_01709 appears to be an outlier, as shown
by the branch lengths denoting relative sequence similarities.
Antimicrobial susceptibility testing. Given the identity of
RarA with the other AraC-type proteins such asMarA and RamA,
we hypothesized that RarAmight possess similar functional prop-
erties in conferring low-level multidrug resistance. In order to
address this, we cloned the open reading frame encoding rarA
with its putative promoter region into pACYC177 or pACYC184
and determined the multidrug resistance phenotype conferred by
this regulator in both wild-type E. coli and K. pneumoniae strains
as well as in strains harboring deletions in various loci such as
marA, ramA, and the efflux operon acrAB (Table 1). Overexpres-
sion of rarA in themarA strain (E. coliK-12MG1655marA) led
to increases inMICs as follows: a 2-fold increase in the tigecycline
MIC, 4-fold increases in the ciprofloxacin, norfloxacin, and tetra-
cyclineMICs, and an 8-fold increase in the chloramphenicol MIC
(Table 3). Similarly, in the AG100 soxS rob marA strain, the
increased expression of pACrarA-2 resulted in increases in the
olaquindox and ciprofloxacin MICs (2-fold) and the tigecycline
and norfloxacin MICs (8-fold) relative to the MICs seen
with the vector-only control (Table 3). However, when the
pACrarA-2 construct was overexpressed in AG100A, there were
no differences in the susceptibility profiles in comparison to the
vector-only control, implying that themultidrug-resistant pheno-
type is dependent on the presence of a functional acrAB efflux
TABLE 2 List of primers used in experiments
Primer Sequence (5=–3=)a
Cloning
02968FB CGGGATCCCACTATCGCGGCGATTGTA
02968RS AAAAGTACTTCATGCGGATCGCTGACG
02968HR CCCAAGCTTTCATGCGGATCGCTGACG
02968BF CGGGATCCTTGCACTTTATGTGCGGT
OqxRbamHIF CGGGATCCTTTACTTCGCAGGCTAAC
OqxRsca1R AGTACTTCATTTTCTGGTGACGAAAA
Deletion
Ci-02968 CCGTTCCAAGCGGCCGCAAGAGCGCATCTCGTCA
GCGATCCGCATG
Co-02968 AAAAAGTCGACTCAGTCCTGACCCGGCCCATG
Ni-02968 CGCTCTTGCGGCCGCTTGGAACGGTCGCGGCCG
GTTAAAAGCATC
No-02968 AAAAACTGCAGGTATGGACTAATTTATCGGTGC
02968delchkF TCAGCCAGATGGCAACCG
02968delchkR ACCGCTTCAATGCGACCG
Ci-acrB CGCTCTTGCGGCCGCTTGGAACGGGGCGCGCCT
CTCCTGGTT
Co-acrB AAAAACTCGAGCCACTTTTGCAAATCCGTAGAG
Ni-acrA CGCTCTTGCGGCCGCTTGGAACGGGTGTCCAATT
TCAAAATGTTC
No-acrA AAAAACTGCAGGCGTAGCGTCGGG CAGAATTG
AcrABdelchkF GAGCGAATGTGGCAATGTGC
AcrABdelchkR CACGGTCATTTCACCGACG
Sequencing
02968FB CGGGATCCCACTATCGCGGCGATTGTA
02968RS AAAAGTACTTCATGCGGATCGCTGACG
02698intF GACAGATCCTGAATGAT
02698intR TGAATGTTTCCCCAGGTT
OqxRF GTCACCAGAAAATGATTAATGCGC
OqxRR GCCTTTGCCCGTGAAATCAG
Q-RTPCR
Kp02968F TGGATCGACAACCATCTTGA
Kp02968R AAGGACTGCTGGGAGTCAAA
Kp_16SQ_F GTTACCCGCAGAAGAAGCAC
Kp_16SQ_R CTACGCATTTCACCGCTACA
02969F AAGGTGCTGGTGAAGTCGAT
02969R GGAGACGAGGTTGGTATGGA
Kp_ramAQ_F AGCCTGGGGCGCTATATT
Kp_ramAQ_R GTGGTTCTCTTTGCGGTAGG
Kp_marAF TCGAGGATAACCTGGAATCG
Kp_marAR ACAAATGGGCTCATTGCTC
oqxRqpcrF TAACGAAGCCTGCTCTGCTT
oqxRqpcrR AATGGTTCCGCTAACTCGTG
5= RACE
GSP1 ATGTCTGCGCAACAG
GSP2 GCTCGTCGGGCAACGGTGTC
GSP3 CCAGACGGCTATCAAGATGGTTG
a Underlined sequences denote restriction enzyme cut sites.
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pump. Regardless of the absence of marA, soxS, or rob, either
singly or in combination, overexpression of rarA resulted in a
low-level multidrug resistance phenotype in E. coli (Table 3).
Correspondingly, in K. pneumoniae Ecl8 ramA, the absence
of ramA did not affect the multidrug-resistant phenotype when
rarA was overexpressed (Table 4). The increases in MIC ranged
from 2-fold for tetracycline and norfloxacin to 4-fold for olaquin-
dox, ciprofloxacin, and tigecycline and 8-fold for chlorampheni-
col. The deletion of the rarA open reading frame (Ecl8 rarA)
resulted in a 2- to 8-fold reduction inMIC (Table 4). As expected,
the complementation of the rarA regulator in trans resulted in
MIC levels higher than that observed for the parental strains. Sim-
ilar to the experiments in E. coli, overexpression of rarA in K.
pneumoniae Ecl8 acrAB did not result in an MDR phenotype
(Table 4).
Geneexpression levelsof rarA in clinicalmultidrug-resistant
isolates of K. pneumoniae. In order to establish a role for rarA in
clinical resistance, we determined by quantitative real-time RT-
PCR whether rarA was upregulated in clinical isolates of K. pneu-
moniae obtained from various geographical locations. In our sur-
vey, we included 17 multidrug-resistant strains collected from
Chile, Turkey, andGermany, where our results show that of the 17
strains tested, 7 overexpressed rarA-specific transcripts compared
to the sensitive K. pneumoniae strain Ecl8 (see Fig. 3), including
two Turkish isolates, TS152 (6.62-fold) and TS165 (3.77-fold), as
well as one from Chile (TS202; 7.37-fold). Most of the isolates
from Germany also showed overexpression of the rarA regulator
(GC9, 9.6-fold; GC12, 7.91-fold; GC19, 8.24-fold; GC21, 8.09-
fold). For those strains that overexpressed rarA, we were also able
to demonstrate that the levels of either marA or ramA were also
elevated (4- to 5-fold) among all isolates showing expression (data
not shown). Furthermore, analyses of rarA and oqxA levels in the
constitutive rarA expresser,K. pneumoniae strain Ecl8/pACrarA-1
(Table 1), demonstrated the increased transcription of both genes
(see Fig. 3).
In all the strains where rarA overexpression was noted, we
sought to determine the molecular basis of upregulation by ini-
tially focusing on identifying changes within the promoter and
associated regions of the rarA regulator by (i) determining the
transcriptional start site of rarA, (ii) mapping the changes within
the intergenic region between rarA and the oqxAB operon relative
to the transcription-relevant sequences (Fig. 2), and (iii) deter-
mining the sequence of the rarA regulator itself.
DNA sequence analyses of the intergenic region and ORF of
the rarA regulator. (i) Intergenic region. Sequence analyses
TABLE 3 Susceptibility profiles of E. coli strains transformed with pACrarA and vector-only controla
Strain
MIC (g/ml)
CHL OQX TET TIG NOR CIP
AG100 4 16 4  0.500 0.125 0.031
AG100/pACrarA-1 16 32 8 2 1 0.062
AG100/pACYC177 4 16 4  0.500 0.125 0.031
AG100/pACrarA-2 * 32 * 2 0.250 0.062
AG100/pACYC184 * 16 *  0.5 0.125 0.031
AG100A * 8 * 0.250 0.008 0.004
AG100A/pACrarA-2 * 8 * 0.250 0.008 0.004
AG100A/pACYC184 * 8 * 0.250 0.008 0.004
AG100 soxS rob marA * 16 * 0.500 0.032 0.031
AG100 soxS rob marA/pACrarA-2 * 32 * 4 0.250 0.062
AG100 soxS rob marA/pACYC184 * 16 * 0.500 0.031 0.031
MG1655 4 16 4 4 0.500 0.062
MG1655/pACrarA-1 16 32 8 8 1 0.125
MG1655/pACYC177 4 16 4 4 0.500 0.062
MG1655 marA 4 8 4 4 0.250 0.031
MG1655 marA/pACrarA-1 32 16 16 8 1 0.125
MG1655 marA/pACYC177 4 8 4 4 0.250 0.031
a A pACYC177 or pACYC184 backbone was used to clone the rarA open reading frame. Depending on the resistance cassettes already in situ, the appropriate recombinant
constructs would be used. Asterisks denote that MIC testing for that particular antibiotic was not done due to presence of a conflicting antibiotic resistance cassette on the plasmid
and/or construct. Entries in bold denote increased MICs over those seen with wild-type/parental strains. CHL, chloramphenicol, OQX, olaquindox, TET, tetracycline, TIG,
tigecycline, NOR, norfloxacin, CIP, ciprofloxacin.
TABLE 4 Susceptibility profiles of K. pneumoniae strains transformed
with pACrarA and vector-only controla
Strain
MIC (g/ml)
CHL OQX TET TIG NOR CIP
Ecl8 4 16 4 2 0.250 0.031
Ecl8/pACrarA-1 8 32 8 4 0.500 0.062
Ecl8/pACYC177 4 16 4 2 0.250 0.031
Ecl8 ramA 0.5 8 1 1 0.250 0.016
Ecl8 ramA/pACrarA-1 4 32 2 4 0.500 0.062
Ecl8 ramA/pACYC177 0.5 8 1 1 0.250 0.016
Ecl8 rarA * 8 * 0.500 0.031 0.016
Ecl8 rarA/pACrarA-2 * 64 * 4 0.250 0.062
Ecl8 rarA/pACYC184 * 8 * 0.500 0.031 0.016
Ecl8 acrAB * 2 * 0.25 0.031 0.016
Ecl8 acrAB/pACrarA-2 * 64 * 0.25 0.031 0.016
Ecl8 acrAB/pACYC184 * 2 * 0.25 0.031 0.016
a A pACYC177 or pACYC184 backbone was used to clone the rarA open reading frame.
Depending on the resistance cassettes already in situ, the appropriate recombinant
constructs would be used. Asterisks denote that MIC testing for that particular
antibiotic was not done due to presence of a conflicting antibiotic resistance cassette on
the plasmid and/or construct. Entries in bold denote increased MICs over those seen
with wild-type/parental strains. CHL, chloramphenicol; OQX, olaquindox; TET,
tetracycline; TIG, tigecycline; NOR, norfloxacin; CIP, ciprofloxacin.
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within the intergenic region for detection of polymorphisms high-
lighted changes within many of the rarA-overexpressing strains
(Fig. 2). To clarify the possible significance of these intergenic
changes, we performed 5= RACE experiments using strain K.
pneumoniae Ecl8Mdr1 to determine the transcription start site
(TSS), which maps 58 bp upstream of the open reading frame of
rarA (Fig. 2). Notably, none of the rarA-overexpressing clinical
strains showed changes within regions, e.g., the rarA TSS,10 or
35 hexamer, relevant to gene transcription (Fig. 2). In contrast,
all of the rarA-overexpressing strains (TS152, TS165, Kp342, GC9,
GC12, GC19, and GC21), with the exception of Ecl8MDR1 and
TS202, harbored changes approximately 121 to 131 bp upstream
of the rarA open reading frame (Fig. 2), where the most common
change was a C insertion at 131 bp (Fig. 2). However, two of the
rarA overexpressers (GC12 and GC21) showed identical changes
(C8¡T and T11¡G) within the putative Shine-Dalgarno se-
quence (Fig. 2). Interestingly, no changes were found in multi-
drug-resistant strains Ecl8Mdr1 and TS202, but those strains still
overexpressed rarA. Our findings suggest that the molecular basis
for rarA upregulation may not be linked to the changes identified
within the intergenic region.
(ii) rarA regulator. Only 4 (GC19, Ecl8, Ecl8Mdr1, and
Kp342) of the 10 strains sequenced (9 rarA overexpressers and the
sensitive Ecl8 strain) harbored changes within the rarA regulator.
Identical mutations in rarA leading to a Glu96¡Arg substitution
were found in both nonexpresser K. pneumoniae Ecl8 and rarA
overexpresser K. pneumoniae Ecl8Mdr1. This change is located
within the -helix in the predicted HTH binding site (http:
//bioinf.cs.ucl.ac.uk/psipred/); however, its presence in both
strains implies that it is not a crucial residue. Several substitutions
not present in other strains were identified in K. pneumoniae
Kp342: Ala31¡Ser, Lys57¡Gln, Ile63¡Val, Val111¡Ala,
Ala112¡Glu, and Thr114¡Ala. This strain also harbors a muta-
tion at position Arg117¡STOP which leads to a premature stop
codon (TGA). Of all the other clinical isolates that overexpress
rarA, only GC9 showed a unique change, Gln99¡Lys, within the
sequence between helices 6 and 7, proximal to the C-terminal end
of the protein.
The oqxAB (KPN_02969 and KPN_02970) efflux operon lies
downstream from the rarA regulator where the oqxAB pump has
been associated with reduced susceptibility to olaquindox, cipro-
floxacin, and chloramphenicol (15). Interestingly, all clinical
FIG 2 Nucleotide changes within the intergenic region between KPN_02968 (rarA) and KPN_02969 (oqxA). Changes observed within the intergenic region
between rarA and oqxA in the different clinical strains tested are shown. The numbering scheme is based on the first nucleotide before the ATGof rarA as position
1. The transcription start site of rarA, determined by 5= RACE analysis, is labeled TSS. The Shine-Dalgarno sequence is underlined; putative 10 and 35
promoter regions determined through Softberry analysis are shown boxed and labeled accordingly.
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strains that showed upregulation of rarA also demonstrated in-
creased expression of KPN_02969 (oqxA) (Fig. 3). In order to
dissect the molecular basis for this upregulation, we determined
the following: (i) whether there was an association between rarA
and oqxAB upregulation and (ii) whether the GntR-type regulator
(OqxR_KPN_02971) encoded downstream of the oqxAB operon
would function as a repressor.
Our results show that plasmid-mediated overexpression of
rarA resulted in increased levels of oqxA in K. pneumoniae Ecl8
and Ecl8rarA (Fig. 3). Additionally, a reproducible (1.5-fold,
mean of 4 experiments) increase in acrAB levels was also observed
in the same strains. Therefore, we surmise that rarAmay function
as a positive regulator of oqxAB and acrAB levels.
Putative regulator OqxR. (i) Sequencing results.We first se-
quenced all the rarA- and oqxAB-overexpressing strains and
found that not all strains (e.g., TS202) that overexpressed oqxA
(KPN_02969) harbored changes within the oqxR gene (Table 5).
However, there were several recurring changes, namely,
Gln11¡Leu (GC12 and GC21), Asp95¡Glu (GC12 and GC21),
Val113¡Ile (GC12, GC21, and and KP342) and Val130¡Ala
(TS152 and TS165). Based on alignments with other GntR family
regulators, Gln11¡Leu is located within the DNA-binding do-
main of the winged helix-turn-helix (WHTH) ofOqxR. The other
mutations were located within the predicted C-terminal effector
binding and oligomerization domain (26).
(ii) oqxR overexpression effects on 02969 (oqxA) levels. In
order to confirm that the mutations noted within OqxR would be
directly associated with increased expression of the oqxAB efflux
FIG 3 Fold change in expression levels of rarA and oqxA among clinical isolates compared toK. pneumoniae Ecl8. All QPCR experiments were performed as outlined
in Materials and Methods. For strains Ecl8Mdr1 [represented by EcL8(R)], Kp342, TS152, TS165, TS202, GC9, GC12, GC19, and GC21, fold change values were
generated after normalizing to 16S levels for each strain and thenusing oqxA and rarA levels derived from the sensitiveK. pneumoniaeEcl8 strain. To assesswhether rarA
could activate the expression of the efflux pump oqxAB, transcription of oqxAwas assessed in Ecl8/pACrarA-1 [EcL8(P)] and Ecl8rarA/pACrarA-2 [EcL8()]. In this
case, the fold change was normalized as mentioned before but calibrated against either Ecl8/pACYC177 or Ecl8rarA/pACYC184.
TABLE 5 Sequence analysis of OqxR and rarA/oqxA expression levels of clinical K. pneumoniae isolatesa
Strain OqxR change(s)
Expression level of rarA
calibrated against Ecl8
Con/Comp log2 expression
level(s)b
rarA oqxA
152 Val130¡Ala 6.62 — 6.42/—
165 Arg25¡His, Val130¡Ala 3.77 — 4.76/—
202 Ala133¡Thr 7.37 — 5.64/—
GC9 Phe6¡Ser 9.60 17.97/17.53 8.68/1.4
GC12 Gln11¡Leu, Asp95¡Glu, V113¡Ile 7.91 21.77/23.6 2.89/0.64
GC19 Frameshift , aa 73-77 8.24 21.06/20.84 7.6/0.74
GC21 Gln11¡Leu, Asp95¡Glu, Val 113¡Ile 8.09 23.34/21.75 3.72/0.01
Kp342 Asn38¡Thr, Asp95¡Glu, Val113¡Ile, His159¡Leu 6.21 21.76/22.03 1.77/0.735
Ecl8Mdr1 Frameshift , aa 88-94 10.46 17.88/17.44 9.06/0.28
a Strains whose names are underlined were complemented with pACoqxR. Boldface font denotes amino acid changes present in several strains. Expression levels of rarA calibrated
against sensitive K. pneumoniae strain Ecl8 are shown.
b Con, control data representing either the wild-type or vector-only strains (pACYC177); Comp, complementation data representing increases or decreases of rarA or oqxA
expression levels in the different strains after complementation with pACOqxR. Negative values indicate reduction of oqxA levels below the levels noted in the vector-only
calibrators. —, strains not complemented due to high levels of innate kanamycin resistance. aa, amino acids.
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pump, we performed complementation assays with wild-type
oqxRon strains (Ecl8Mdr1,GC9,GC12,GC19,GC21, andKp342)
that overexpressed oqxAB. QPCRanalyses showed that oqxA levels
were lower in all of the complemented strains than in the vector-
only control strains, while rarA levels remained unaffected (Table
5). Only two (Kp342 and Ecl8Mdr1) of the six strains were found
to show reductions in olaquindox MICs (Table 6). The lack of
reduction in olaquinodox MICs noted for the clinical strains
(GC9, GC12, GC19, and GC21) may have been due to other
mechanisms (Table 6). In all strains (Ecl8Mdr1, GC9, GC12,
GC19, GC21, and Kp342) where we expressed the recombinant
oqxR, we also ascertained that the levels of the AcrA protein
(Western blot analyses for the AcrA protein; data not shown) re-
mained identical to those of the vector-only controls. From our
results, we surmise that a decrease in oqxAB transcription does
result in the reduction of olaquindox MICs for some strains.
DISCUSSION
In this work, we have characterized a novel AraC regulator,
KPN_02968 (rarA), in K. pneumoniae. We demonstrate that plas-
mid-mediated overexpression of rarA produces a multidrug-re-
sistant phenotype in either E. coli orK. pneumoniae independently
of the presence ofmarA, soxS, or rob (29) but requires the presence
of a functional efflux pump, acrAB, to exhibit the multidrug-re-
sistant phenotype (Table 3 and Table 4). In clinical isolates where
we find upregulation of the rarA gene, there appears to be a con-
current increase in the levels of transcripts of oqxAB, which en-
codes an efflux pump that has been previously implicated in me-
diating resistance to ciprofloxacin and olaquindox (15, 17).
In K. pneumoniae MGH 78578, oqxAB is flanked by genes
encoding two regulators, RarA (KPN_02968) and OqxR
(KPN_02971). We first tried to ascertain whether plasmid-medi-
ated overexpression of rarA in a genetically manipulated K. pneu-
moniae strain would result in the upregulation of the oqxAB
operon. Our results show that the plasmid-mediated overexpres-
sion of rarA does result in the increased expression of oqxAB (Fig.
3). In contrast, the introduction of wild-type oqxR in trans re-
pressed the oqxAB transcripts (Table 5), which did result in reduc-
tions to olaquindox in two strains (Ecl8Mdr1 and Kp342) (Table
6).We surmised that the lack of the reduction in theMICsmay be
due to AcrA levels which mask the decrease in the MIC or that
other alternate mechanisms for olaquindox resistance exist in
these strains which may compensate for the reduction of the
oqxAB levels.Western blot analyses showed that the levels of AcrA
protein remained unaltered (data not shown). Taken together, the
results suggest that oqxAB may be subject to regulation by both
RarA (activator) and OqxR (repressor).
The sequencing of the oqxR gene in all the strains where rarA
and oqxAB levels were elevated revealed several recurring changes,
namely, Gln11¡Leu (located in strains GC12 and GC21),
Asn95¡Glu andVal113¡Ile (located in strainsGC12,GC21, and
Kp342), and Val130¡Ala (located in strains TS152 and TS165).
On the basis of our complementation studies, we surmise that the
changes associated with producing a mutated OqxR protein are
Phe 6¡Ser, Gln11¡Leu, Asp95¡Glu, Val113¡Ile, and the
frameshift deletion spanning positions 73 to 77 or positions 88 to
94. Further experiments are under way to determine whether all
other changes reported here are also detrimental to OqxR func-
tion.
Seven out of 17 of the clinical multidrug-resistant strains that
we tested overexpressed rarA as well as either ramA or marA.
While it is clear that decreased susceptibility occurred with rarA
overexpression in the absence of marA, soxS, and rob, the coex-
pression of the other AraC regulators in multidrug-resistant clin-
ical strains is not uncommon (6, 23). Despite the small number of
isolates reported here that exhibited rarA overexpression, we find
that rarA upregulation is not confined only to clinical isolates
from geographically diverse locations but is also noted in the plant
endophyte Kp342. Genome analyses of this plant endophyte did
indicate that it was multidrug resistant, but the molecular basis of
this resistance was not evident from sequence analyses of the com-
monly encountered mutations (9). Our finding here suggests that
the reason for the decreased susceptibility noted in Kp342 may be
linked to the upregulation of rarA. However, to exactly pinpoint
the relative contributions of the transcriptional regulators rarA,
ramA, and marA and the efflux pumps acrAB and oqxAB, multi-
drug-resistant clinical isolates should be subjected to specific ge-
netic manipulations and complementation experiments. In con-
clusion, our data show that K. pneumoniae encodes another
multidrug resistance regulator, RarA, which functions as an acti-
vator of the oqxAB efflux pump,which is itself negatively regulated
by OqxR.
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